12月30日 - InflaRx N.V. 发布关于Vilobelimab治疗坏疽性脓皮病三期临床试验数据分析的最新动态。该公司宣布，由于试验未能达到预期疗效终点，Vilobelimab的三期研究已被终止。
InflaRx同时表示，计划与美国食品药品监督管理局（FDA）举行会议，共同探讨该药物在坏疽性脓皮病治疗领域的后续开发路径。值得注意的是，后续进行的回溯性分析数据显示，Vilobelimab呈现出积极的治疗趋势。这些分析结果提示该药物可能具有持续性的治疗效果信号，为后续研究提供了有价值的方向。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.